Pharmacotherapy of type ii diabetes mellitus: estimation of consumption of oral hypoglycemic agents at the ukrainian pharmaceutical market


  • O. M. Kyrychenko National University of Pharmacy, Ukraine
  • O. A. Kyrychenko National University of Pharmacy, Ukraine
  • O. I. Leonchenko National University of Pharmacy, Ukraine



type ІІ diabetes mellitus, consumption analysis, oral hypoglycemic agents, ATC/DDD methodology


The consumption of oral hypoglycemic agents (OHAs) for the period of 2008 – 2013 at the Ukrainian market has been analyzed. The increase in consumption of OHAs by 1.92 times in 2013 according to DDDS/1000/d value was found compared to 2008. The proportion of patients with type II DM (44.20%) consuming daily 1 DDD OHA has been determined, and discrepancy of the volumes of consumption with the registered morbidity has been found. The structure of consumption of OHAs has been considered: 98.95% of the total volume belongs to 2 groups – sulphonylurea derivatives (73.84%) and biguanides (25%), and only 1.16% – to other groups of OHAs. The comparative analysis of the volume and the structure of consumption in Ukraine with some European countries has been conducted. The consumption volumes of OHAs according to DDDS/1000/d value is higher by 4.88-2.68 times in European countries than in Ukraine. According to the structure of consumption in European countries, unlike Ukraine, biguanides are more consumed (with the share of 38.50 to 48.00% of the total volume). The difference in consumption determined indicates diagnosing at the stage of potential diabetes and at early stages of the disease development; it allows to compensate carbohydrate disorders by drug-free methods and biguanides. High consumption of sulphonylurea derivatives in Ukraine is due to the appropriate glycemic state of the Ukrainian diabetic population, late diagnosis, few educational and preventive measures and low compliance of patients. The need for developing national programmes for the early detection of disorders of the carbohydrate metabolism, early diagnosis to improve the quality of life of patients, prevention of early development of chronic complications of type II DM and reduction of the significant economic costs have been determined.


Аметов А.С., Демидова Т.Ю., Ерохина Е.Н. // Рус. мед. журн. – 2006. – №26. – С. 1878-1883.

Демидова Т.Ю. // Проблемы эндокринол. – 2012. – №6. – С. 53-59.

Довідник основних показників діяльності ендокринологічної служби України за 2013 рік // Ендокринол. Додаток 1. – 2014. – Т. 19, №1. – С. 40.

Кравчун Н.А., Ильина И.М. // Междунар. эндокринол. журн. – 2013. – №6 (54). – С. 37-40.

Маньковский Б.Н. // Ліки України. – 2011. – №10 (156). – С. 14-19.

Маньковский Б.Н. Скрининг и своевременная диагностика сахарного диабета – залог успешной профилактики диабетических осложнений. Режим доступу:

Недосугова Л.В. // Сахарный диабет. – 2011. – №2. – С. 99-109.

Полозова Л.Г. // Междунар. эндокринол. журн. – 2013. – №4 (52). Режим доступу:

Полторак В.В., Горшунская М.Ю., Шеметило А. // Проблеми ендокринної патол. – 2010. – №4. – С. 94-105.

Полторак В.В., Кравчун Н.А., Горшунская М.Ю., Красова Н.С. // Междунар. эндокринол. журн. – 2014. – №1 (57). – С. 77-89. 11. Baltic Statistics on Medicines 2010-2012: Режим доступу: http://

Drug Consumption in Norway 2008-2012. Norwegian Institute of Public Health. – Oslo, legemiddelstatistikk, 2013. – 1. – P. 102.

Dunkley A.J., Bodicoat D.H., Greaves C.J. et al. // Diabetes Care. – 2014. – Vol. 37 (6). – P. 1775-1776. Режим доступу: /content/37/4/922.full.

Knowler W.C., Barrett-Connor E., Fowler S.E. et al. // New Engl. J. Med. – 2002. – Vol. 346. – P. 393-403.

Pichetti S., Sermet C., S. van der Erf // Questions d’economie de la santé. Режим доступу: Publi-cations/QES187.pdf